Ultra high resolution Single Photon Computed Emission Tomography for the molecul...
Ultra high resolution Single Photon Computed Emission Tomography for the molecular imaging of brain disease
MILabs’ radically new proprietary approaches for ultra-high resolution and ultra-sensitive brain SPECT (Single Photon Emission Computed Tomography) enable the measuring of disturbed regional cerebral blood flow (rCBF) perfusion, a...
ver más
¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video
Proyectos interesantes
MINDVIEW
Multimodal Imaging of Neurological Disorders
7M€
Cerrado
SPCCT
In Vivo Spectral Photon Counting CT Molecular Imaging in Car...
6M€
Cerrado
RETIMAGER
REAL TIME MOLECULAR IMAGER WITH UNSURPASSED RESOLUTION
3M€
Cerrado
TEC2014-56600-R
TECNOLOGIA PARA EL ESTUDIO INTEGRADOR DEL CEREBRO
88K€
Cerrado
SAF2014-56330-R
EVALUACION DE LA PERFUSION CEREBRAL Y LA CONECTIVIDAD FUNCIO...
91K€
Cerrado
Duración del proyecto: 6 meses
Fecha Inicio: 2015-04-20
Fecha Fin: 2015-10-31
Líder del proyecto
Milabs BV
No se ha especificado una descripción o un objeto social para esta compañía.
TRL
4-5
Presupuesto del proyecto
71K€
Fecha límite de participación
Sin fecha límite de participación.
Descripción del proyecto
MILabs’ radically new proprietary approaches for ultra-high resolution and ultra-sensitive brain SPECT (Single Photon Emission Computed Tomography) enable the measuring of disturbed regional cerebral blood flow (rCBF) perfusion, and characterising plaques and neurotransmitter imbalance - all important hallmarks of brain disorders - at unprecedented spatial resolutions. This new approach has the potential to disrupt the complete field of molecular imaging (MI), a multibillion market worldwide. Current techniques can only measure the mentioned effects in the brain either at late stages of disease progression (at which point the patients have already been diagnosed) or at insufficient resolution to isolate processes in small parts of the brain. Current SPECT results in low resolution images, are highly sensitive to patient movement and are time consuming and costly. MILabs has developed a clinical SPECT prototype, G-SPECT, which has proven its potential to reposition SPECT as the major clinical MI modality. G-SPECT uses a high bandwidth photon detection ring with multiple pinholes, and advanced reconstruction software that compensates for patient movement artefacts. This enables 35-fold higher resolution images, more accurate imaging and lower radiation dose due to shorter scan times (Figure 1). The application of MILabs SPECT technology in small animals has sparked enthusiasm amongst clinicians and brain researchers worldwide.
In this Stage 1 SME Instrument, MILabs will investigate the commercial feasibility of this exciting technology by (i) identifying and assessing those indications to which the clinical utility yield the best initial market value, (ii) developing a sound clinical validation strategy and (iii) defining the route-to-market.